<DOC>
	<DOC>NCT01218308</DOC>
	<brief_summary>This study is designed to test the efficacy of an investigational influenza vaccine, in children compared to HavrixÂ®, a licensed Hepatitis A virus vaccine. This study will also evaluate the immunogenicity and safety of the investigational vaccine.</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects who the investigator believes that they and/or their parent(s) or legally acceptable representative(s) can and will comply with the requirements of the protocol. A male or female child aged between 3 and 8 years inclusive at the time of the first vaccination; children are eligible regardless of history of administration of influenza vaccine in a previous season. However, subjects who have received any seasonal or pandemic influenza vaccine within 6 months preceding the first dose of study vaccine will not be enrolled. Written informed consent obtained from the subject/from the parent(s)/legally acceptable representative(s) of the subject. Written assent obtained from the subject if/as required by local regulations. Subjects in stable health as determined by investigator's clinical examination and assessment of subjects' medical history. Access to a consistent means of telephone contact Child in care. Use of an investigational or nonregistered product other than the study vaccines within 30 days before study vaccination or planned use during study period. Routine registered childhood vaccinations are permitted. Prior receipt of any seasonal or pandemic influenza vaccine within 6 months preceding the first dose of study vaccine, or planned use of such vaccines during the study period. Prior receipt of more than one dose of a licensed hepatitis A vaccine, with the first dose administered at &gt;=12 months of age. Chronic administration of immunosuppressants or other immunemodifying drugs within 6 months prior to the first vaccine dose. Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period. History of GuillainBarre syndrome within 6 weeks of receipt of prior influenza virus vaccine. Any known or suspected allergy to any constituent of influenza vaccines ; a history of anaphylactictype reaction to constituent of vaccine; or a history of severe adverse reaction to a previous influenza vaccine. Fever at the time of enrolment. Acute disease at the time of enrolment. Any significant disorder of coagulation or treatment with Coumadin derivatives or heparin. Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. Ongoing aspirin therapy. Any other condition which, in the opinion of the Investigator, prevents the subject from participating in the study.</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Influenza</keyword>
</DOC>